{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Morera DS"],"funding":["NCI NIH HHS"],"pagination":["62-72"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8327783"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["203(1)"],"pubmed_abstract":["<h4>Purpose</h4>Studies indicate that molecular subtypes in muscle invasive bladder cancer predict the clinical outcome. We evaluated whether subtyping by a simplified method and established classifications could predict the clinical outcome.<h4>Materials and methods</h4>We subtyped institutional cohort 1 of 52 patients, including 39 with muscle invasive bladder cancer, an Oncomine™ data set of 151 with muscle invasive bladder cancer and TCGA (The Cancer Genome Atlas) data set of 402 with muscle invasive bladder cancer. Subtyping was done using simplified panels (MCG-1 and MCG-Ext) which included only transcripts common in published studies and were analyzed for predicting metastasis, and cancer specific, overall and recurrence-free survival. TCGA data set was further analyzed using the Lu"],"journal":["The Journal of urology"],"pubmed_title":["Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA."],"pmcid":["PMC8327783"],"funding_grant_id":["F31 CA236437","R01 CA227277","F31 CA210612","R01 CA176691"],"pubmed_authors":["Morera DS","Stenzl A","Hasanali SL","Belew D","Wang J","Merseburger AS","Ghosh S","Jordan AR","Terris MK","Lokeshwar VB","Klaassen Z","Soloway MS","Bollag RJ"],"additional_accession":[]},"is_claimable":false,"name":"Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA.","description":"<h4>Purpose</h4>Studies indicate that molecular subtypes in muscle invasive bladder cancer predict the clinical outcome. We evaluated whether subtyping by a simplified method and established classifications could predict the clinical outcome.<h4>Materials and methods</h4>We subtyped institutional cohort 1 of 52 patients, including 39 with muscle invasive bladder cancer, an Oncomine™ data set of 151 with muscle invasive bladder cancer and TCGA (The Cancer Genome Atlas) data set of 402 with muscle invasive bladder cancer. Subtyping was done using simplified panels (MCG-1 and MCG-Ext) which included only transcripts common in published studies and were analyzed for predicting metastasis, and cancer specific, overall and recurrence-free survival. TCGA data set was further analyzed using the Lu","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jan","modification":"2025-04-04T02:12:32.348Z","creation":"2022-02-11T01:59:51.507Z"},"accession":"S-EPMC8327783","cross_references":{"pubmed":["31112107"],"doi":["10.1097/ju.0000000000000351","10.1097/JU.0000000000000351"]}}